Florentina Teofilovici

1.0k total citations
27 papers, 529 citations indexed

About

Florentina Teofilovici is a scholar working on Molecular Biology, Computational Theory and Mathematics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Florentina Teofilovici has authored 27 papers receiving a total of 529 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 10 papers in Computational Theory and Mathematics and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Florentina Teofilovici's work include Heat shock proteins research (16 papers), Computational Drug Discovery Methods (10 papers) and ATP Synthase and ATPases Research (5 papers). Florentina Teofilovici is often cited by papers focused on Heat shock proteins research (16 papers), Computational Drug Discovery Methods (10 papers) and ATP Synthase and ATPases Research (5 papers). Florentina Teofilovici collaborates with scholars based in United States, United Kingdom and Spain. Florentina Teofilovici's co-authors include Louis Lacombe, Leah Isakov, Henryk Zieliński, Bernard Escudier, Gorelov Ai, Axel Hoos, Christopher G. Wood, Renu Gupta, Peter Mulders and Robert C. Flanigan and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Florentina Teofilovici

27 papers receiving 520 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Florentina Teofilovici United States 11 340 207 185 170 65 27 529
Tomoko Smyth United Kingdom 12 376 1.1× 202 1.0× 159 0.9× 86 0.5× 47 0.7× 33 631
Kazunori Yokomine Japan 10 283 0.8× 236 1.1× 205 1.1× 52 0.3× 42 0.6× 18 503
Kelli Oswald United States 7 437 1.3× 68 0.3× 127 0.7× 66 0.4× 43 0.7× 9 632
Chiara Massa Germany 16 325 1.0× 379 1.8× 291 1.6× 72 0.4× 141 2.2× 42 733
Eleanor Herbert United Kingdom 8 291 0.9× 153 0.7× 182 1.0× 53 0.3× 89 1.4× 11 568
Wansong Lin China 16 387 1.1× 163 0.8× 209 1.1× 44 0.3× 233 3.6× 35 653
Seiji Hosaka Japan 7 266 0.8× 143 0.7× 140 0.8× 39 0.2× 75 1.2× 20 538
Jürgen Bukur Germany 13 279 0.8× 256 1.2× 136 0.7× 96 0.6× 114 1.8× 16 590
Charles Ming Lok Chan China 15 283 0.8× 52 0.3× 252 1.4× 108 0.6× 171 2.6× 20 598
Indranil Basu United States 9 344 1.0× 70 0.3× 158 0.9× 50 0.3× 33 0.5× 17 543

Countries citing papers authored by Florentina Teofilovici

Since Specialization
Citations

This map shows the geographic impact of Florentina Teofilovici's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florentina Teofilovici with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florentina Teofilovici more than expected).

Fields of papers citing papers by Florentina Teofilovici

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florentina Teofilovici. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florentina Teofilovici. The network helps show where Florentina Teofilovici may publish in the future.

Co-authorship network of co-authors of Florentina Teofilovici

This figure shows the co-authorship network connecting the top 25 collaborators of Florentina Teofilovici. A scholar is included among the top collaborators of Florentina Teofilovici based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florentina Teofilovici. Florentina Teofilovici is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pillai, Rathi N., Dean A. Fennell, Vladimir Kovčin, et al.. (2019). Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non–Small-Cell Lung Cancer (GALAXY-2). Journal of Clinical Oncology. 38(6). 613–622. 53 indexed citations
2.
Pillai, Rathi N., Dean A. Fennell, Vladimir Kovčin, et al.. (2017). PL03.09: Phase 3 Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, with Docetaxel versus Docetaxel in Advanced Non-Small Cell Lung Cancer (GALAXY-2). Journal of Thoracic Oncology. 12(1). S7–S8. 12 indexed citations
3.
Reck, Martin, James Chih‐Hsin Yang, Pieter E. Postmus, et al.. (2017). JAVELIN Lung 100: updated design of a phase 3 trial of avelumab vs platinum doublet chemotherapy as first-line (1L) treatment for metastatic or recurrent PD-L1+ non-small-cell lung cancer (NSCLC). Annals of Oncology. 28. v492–v492. 5 indexed citations
4.
Ramalingam, Suresh S., Bojan Zarić, Timur Cerić, et al.. (2014). Galaxy-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma.. Journal of Clinical Oncology. 32(15_suppl). TPS8118–TPS8118. 5 indexed citations
5.
Fennell, Dean A., Glenwood Goss, Mark A. Socinski, et al.. (2013). GALAXY-2 trial: A randomized phase III study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced non-small cell lung adenocarcinoma.. Journal of Clinical Oncology. 31(15_suppl). TPS8126–TPS8126. 1 indexed citations
6.
Awada, Ahmad, Angel Rodriguez, Anthony Kong, et al.. (2013). The ENCHANT-1 trial (NCT01677455): An open label multicenter phase II proof of concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2-positive or triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 31(15_suppl). TPS1136–TPS1136. 2 indexed citations
7.
Ramalingam, Suresh S., Glenwood Goss, Igor Bondarenko, et al.. (2013). A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).. Journal of Clinical Oncology. 31(15_suppl). CRA8007–CRA8007. 21 indexed citations
8.
9.
10.
Kauh, John, R. Donald Harvey, Taofeek K. Owonikoko, et al.. (2012). A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies.. Journal of Clinical Oncology. 30(15_suppl). 3094–3094. 5 indexed citations
11.
12.
Goss, Glenwood, Christian Manegold, Rafael Rosell, et al.. (2012). The GALAXY Trial(NCT01348126): A randomized IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone in subjects with stage IIIB or IV NSCLC.. Journal of Clinical Oncology. 30(15_suppl). TPS7613–TPS7613. 3 indexed citations
13.
14.
Zhou, Dan, Florentina Teofilovici, Yuan Liu, et al.. (2012). Associating retinal drug exposure and retention with the ocular toxicity profiles of Hsp90 inhibitors.. Journal of Clinical Oncology. 30(15_suppl). 3086–3086. 10 indexed citations
15.
Lewis, Colleen, John Kauh, Akinyemi A. Akintayo, et al.. (2011). 1230 POSTER A Phase 1 and Pharmacokinetic Study of Ganetespib (STA-9090), a Heat Shock Protein 90 Inhibitor, in Combination With Docetaxel in Subjects With Advanced Solid Tumour Malignancies. European Journal of Cancer. 47. S153–S153. 1 indexed citations
16.
Demetri, G. D., Michael C. Heinrich, Bartosz Chmielowski, et al.. (2011). An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.. Journal of Clinical Oncology. 29(15_suppl). 10011–10011. 34 indexed citations
17.
Wong, Kwok‐Kin, Eugene Paschold, Leora Horn, et al.. (2011). An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 29(15_suppl). 7500–7500. 47 indexed citations
18.
19.
Santis, George, et al.. (2008). Phase II feasibility study of autologous vaccine (HSPPC-96) in patients with resectable lung cancer. Journal of Clinical Oncology. 26(15_suppl). 7584–7584. 3 indexed citations
20.
Koelle, David M., Amalia Magaret, Christopher L. McClurkan, et al.. (2008). Phase I Dose-Escalation Study of a Monovalent Heat Shock Protein 70-Herpes Simplex Virus Type 2 (HSV-2) Peptide-Based Vaccine Designed To Prime or Boost CD8 T-Cell Responses in HSV-Naive and HSV-2-Infected Subjects. Clinical and Vaccine Immunology. 15(5). 773–782. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomoko Smyth Breakdown of academic impact, for papers by Kazunori Yokomine Breakdown of academic impact, for papers by Kelli Oswald Breakdown of academic impact, for papers by Chiara Massa Breakdown of academic impact, for papers by Eleanor Herbert Breakdown of academic impact, for papers by Wansong Lin Breakdown of academic impact, for papers by Seiji Hosaka Breakdown of academic impact, for papers by Jürgen Bukur Breakdown of academic impact, for papers by Charles Ming Lok Chan Breakdown of academic impact, for papers by Indranil Basu
Rankless by CCL
2026